KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBT Margin (2016 - 2025)

Historic EBT Margin for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 0.8%.

  • Jazz Pharmaceuticals' EBT Margin fell 182300.0% to 0.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.04%, marking a year-over-year decrease of 220200.0%. This contributed to the annual value of 11.56% for FY2024, which is 37900.0% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported EBT Margin of 0.8% as of Q3 2025, which was down 182300.0% from 70.34% recorded in Q2 2025.
  • Jazz Pharmaceuticals' EBT Margin's 5-year high stood at 22.33% during Q1 2021, with a 5-year trough of 70.34% in Q2 2025.
  • In the last 5 years, Jazz Pharmaceuticals' EBT Margin had a median value of 1.53% in 2022 and averaged 2.28%.
  • Per our database at Business Quant, Jazz Pharmaceuticals' EBT Margin surged by 614700bps in 2021 and then plummeted by -838100bps in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' EBT Margin (Quarter) stood at 5.0% in 2021, then crashed by -600bps to 34.97% in 2022, then soared by 117bps to 6.08% in 2023, then skyrocketed by 101bps to 12.24% in 2024, then tumbled by -93bps to 0.8% in 2025.
  • Its last three reported values are 0.8% in Q3 2025, 70.34% for Q2 2025, and 12.24% during Q4 2024.